Companies heavily reliant on high-volume US generic formulations, such as Lupin, which gets 42% of its revenue from the US, and Dr Reddy's (~34%), face greater valuation pressure. Traditional generic segments operate on thin margins, making them particularly vulnerable to future import duties. Conversely, firms with localized manufacturing, advanced specialty pipelines, or diversified non-US revenue streams have weathered the announcement better.